Diaminocyclohexane platinum complexes

ABSTRACT

Diaminocyclohexane platinum complexes having the structural formula ##STR1## wherein: X is a monovalent anion selected from the group consisting of isoascorbate, monosaccharate, saccharate-4-lactone, shikimate, isethionate, 2-aminoethylsulfate, azetidinecarboxylate, proline, hydroxyproline, pipecolinate, cyclopropanecarboxylate, cyclobutanecarboxylate, cyclopentanecarboxylate, cyclopentenecarboxylate, cyclohexanecarboxylate, cyclohexenecarboxylate, bicine, glycine, 2-aminoethanesulfonate, 2-chloroethanesulfonate and 
     Y is a divalent anion selected from the group consisting of iminodiacetate, isocitratelactone, furanedicarboxylate, cyclopropane-1,1-dicarboxylate, isocitratomonoethylester, N-methyliminodiacetate, N-(2-hydroxyethyl)-iminodiacetate, N-benzyliminodiacetate, N-phenyliminodiacetate, N-(2-acetamido)iminodiacetate, cyclohexane-1,1-diacetate, trans-1,2-cyclopropanedicarboxylate, trans-1,2-cyclobutanedicarboxylate, trans-1,2-cyclopentanedicarboxylate and trans-1,2-cyclohexanedicarboxylate 
     and their use in the treatment of tumors.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. application Ser. No.636,522, filed Aug. 1, 1984, now abandoned. which, in turn, is acontinuation-in-part of application Ser. No. 505,965, filed June 20,1983, now abandoned.

BACKGROUND OF THE INVENTION

The present invention relates to certain novel 1,2-diaminocyclohexaneplatinum complexes and their use in the treatment of tumors.

Recently, certain platinum complexes have been shown by Rosenberg, etal. and others to be highly active anti-tumor agents (see U.S. Pat. Nos.4,177,263 and 4,140,707). For example, the complexcis-dichlorodiamineplatinum-II or "cisplatin" is the chemotherapeuticagent of choice in the treatment of many and varied tumors.

There are several drawbacks, however, associated with the use of theplatinum complexes to treat tumors. Generally, the platinum complexeshave a relatively low solubility in water thereby rendering it difficultto formulate a composition which can effectively deliver the reagent tothe site of the tumor in the body.

Moreover, many of the platinum complexes are highly nephrotoxic therebyfurther restricting their use in the absence of precautionary measuresto avoid damage to the kidneys when administered to animals afflictedwith tumors.

Recently, considerable activity has centered on the use of1,2-diaminocyclohexane complexes of platinum as anti-tumor agents. See,for example, U.S. Pat. Nos. 3,892,790; 3,904,663; 4,115,418; 4,140,707;4,169,846; 4,175,133; 4,228,090 and 4,256,652 and GermanOffenlegungschrift No. 30 22 917.

Although the complexes described therein possess anti-tumor activity,virtually all are highly insoluble in water and are also relativelyhighly nephrotoxic.

German Offenlegungschrift No. 30 22 957 describes1,2-diaminocyclohexane/ascorbate complexes of platinum, useful asanti-tumor agents, which comprise mixtures of complexes having varyingratios of ascorbate ion to platinum. Thus, the publication disclosescomplexes of the formula: ##STR2## wherein n varies from 1.2 to 1.5. Thecomplexes are described as poorly water soluble.

in the Proceedings for the American Association for Cancer Research,Vol. 23, page 116, 1982, we describe New Platinum Complexes ContainingAscorbate having good aqueous solubility, useful antitumor activity anddecreased nephrotoxicity. Two such complexes, one containing Pt,aminoethylpyrrolidine and ascorbate and the second containing Pt,1,2-diaminocyclohexane, chloride and ascorbate are capable ofsuppressing the growth of L1210 cells in vivo.

J. Am. Chem. Soc. 1985, 107, 274-276 describes the synthesis of a seriesof cis-[Pt(RNH₂)₂ ] (ascorbate) complexes which are reported to bestable in aqueous or alcoholic solutions and are active in the S180atumor screen.

We have now found that certain other 1,2-diaminocyclohexane(DACH)-platinum-anion complexes are vastly superior to the ascorbatecomplexes in being relatively non-nephrotoxic, possessing a high degreeof antitumor activity, high water-solubility, and no cross resistance tocis(DACH)-dichlorodiamine platinum II. In particular, we have found thatthe iminodiacetatocyclohexane platinum (II) complexes have marked invitro cytotoxic activity, good in vivo activity as a single injectionwhich is significantly enhanced when administered intraperitoneally andsignificantly less nephrotoxicity than cis-platin.

Especially preferred embodiments of this invention include the mixedisomer DACH-Pt (II) iminodiacetato complexes and the trans-R,R-DACH-Pt(II) mono-iminodiacetato, mono-N-methyl-iminodiacetato,mono-N-hydroxyethyliminodiacetato, mono-N-phenyliminodiacetato, andmono-N-benzyliminodiacetato complexes. These complexes are especiallyvaluable in that they enhance the cytotoxicity without increased hosttoxicity.

It is an object of the present invention to provide non-nephrotoxic1,2-diaminocyclohexane (DACH)-platinum-anion complexes containing 1.0bidentate or 2 monodentate negatively charged organic radicals permolecule of platinum possessing high degrees of anti-tumor activity,high water-solubilities, and no cross resistance to cis-dichlorodiammineplatinum II.

It is a further object of the invention to provide a method for thepreparation of the platinum complexes.

It is a further object of the invention to provide a method forpreparing DACH-platinum-anion complexes containing stoichiometric ratiosof anion to platinum.

It is a further object of the invention to provide a pharmaceuticalcomposition particularly adapted for the treatment of animals afflictedwith tumors.

It is a further object of the invention to provide a therapeutic methodfor the treatment of animals afflicted with tumors.

SUMMARY OF THE INVENTION

The above and other objects of the invention are achieved by thehereinbelow described method which enables the production of complexesof DACH-platinum complexes of the following formulae which containstoichiometric ratios of anion to platinum: ##STR3## wherein: X is amonovalent anion selected from the group consisting of isoascorbate,monosaccharate, saccharate-4-lactone, shikimate, isethionate,2-aminoethylsulfate, azetidinecarboxylate, proline, hydroxyproline,pipecolinate, cyclopropanecarboxylate, cyclobutanecarboxylate,cyclopentanecarboxylate, cyclopentenecarboxylate,cyclohexanecarboxylate, cyclohexenecarboxylate, bicine, glycine,2-aminoethanesulfonate, 2-chloroethanesulfonate, and

Y is a divalent anion selected from the group consisting ofiminodiacetate, isocitratelactone, furanedicarboxylate, cyclopropane-1,1-dicarboxylate and isocitratomonoethyl ester, N-methyliminodiacetate,N-(2-hydroxyethyl)-iminodiacetate, N-benzyliminodiacetate,N-phenyliminodiacetate, N-(2-acetamido)-iminodiacetate,cyclohexane-1,1-diacetate, trans-1,2-cyclobutanedicarboxylate,trans-1,2-cyclopentanedicarboxylate andtrans-1,2-cyclohexanedicarboxylate

The present invention is comprised of a central platinum metalcoordinated to the DACH molecule and either two identical monodentatesor one bidentate. Although cis and trans platinum complexes may bepossible, the preferred geometric isomers are the squareplanarcis-platinum(II) complexes.

In addition, the DACH molecule contains two chiral centers, and,therefore, exists as either the cis-diastereomer or thetrans-diastereomer. Although the cis-diastereomer is optically inactive,the transdiastereomer exists in two enantiometric forms: thetrans-R,R-DACH and the trans-S,S-DACH. The trans-DACH are the preferreddiastereomers. Especially preferred are the trans-R,R-DACH. It is to benoted that mixtures of the various isomers mentioned hereinabove arecontemplated to be within the scope of the present invention.

Particularly useful complexes within the scope of the present inventionare cis-bis-ascorbato (trans-R,R-DACH) platinum (II) andcis-bis-ascorbato (trans-S,S-DACH) platinum (II).

The most preferred embodiments of the present invention are theiminodiacetato derivatives of the trans-DACH-platinum complexdes. Ofthese, particularly preferred iminodiacetato derivatives are thetrans-R,R-DACH-Pt(II) complexes of the above formula wherein:

Y is mono-iminodiacetate, mono-N-methyliminodiacetate,mono-N-hydroxyethyliminodiacetate, mono-N-phenyliminodiacetate, andmono-N-benzyliminodiacetate.

The method of the invention for preparing the above-described complexescomprises:

(a) reacting a water-soluble haloplatinate (II) in an aqueous mediumwith DACH to produce a di-halo-(DACH)-platinum (II);

(b) reacting said product of step (a) with a soluble sulfate salt in anaqueous medium to produce sulfato(DACH)-platinum(II);

(c) reacting the product of step (b) with a soluble salt of X or Y toproduce said complex of the above formula, and

(d) recovering said complex.

The present invention also provides a pharmaceutical composition in unitdosage form suitable for administration to an animal afflicted withtumor cells sensitive to a platinum complex of the above formulacomprising a therapeutically anti-tumor effective amount of the platinumcomplex and a pharmaceutically acceptable carrier therefor.

The invention also provides a method for the treatment of an animalafflicted with tumor cells sensitive to a platinum complex of the aboveformula comprising administering to the animal a therapeutically,anti-tumor effective amount of the platinum complex.

DETAILED DESCRIPTION OF THE INVENTION

The complexes of the invention have the following structural formulae:##STR4##

The stoichiometric mono- and bis-anion-(DACH) platinum complexes of theinvention (i.e., containing one divalent anion or two monovalent anionsper molecule of platinum) may be prepared by reacting any suitablewatersoluble haloplatinate (i.e., K₂ PtCl₄) with DACH to produce theintermediate, di-halo-(DACH)platinum(II). The reaction is preferablyeffected in water at room temperature for a time sufficient to drive thereaction to completion, generally from about 6 to 8 hours.

The intermediate di-halo complex is normally a yellow solid precipitatewhich is advantageously isolated from the reaction mixture by filtering,followed by washing with water, methanol and acetone. Finally, theyellow solid is dried, preferably under vacuum or is left in solutionand immediately reacted therein with a sulfate. It is preferred toutilize a sulfate of a metal or cation the halo salt of which isinsoluble in water to facilitate isolation of the product. Thus, wherethe di-halo (DACH) platinum is the di-chloro complex, it is preferred toemploy Ag₂ SO₄ thereby facilitating removal of the insoluble by-product,AgCl. The reaction is preferably carried out in an aqueous medium suchas water or in the reaction medium from the first step of the method atroom temperature. The reaction generally goes to completion in fromabout 18 to about 24 hours.

Following removal of the insoluble by-product halide, the intermediatesulfato (DACH-platinum(II)) is isolated by evaporating the yellowfiltrate to dryness, e.g., using a rotary evaporator, as a yellow-brownsolid which is washed, e.g., with acetone and dried, preferably, invacuum. Alternatively, the sulfato-DACH-platinum intermediate is left insolution and reacted therein with a soluble salt of the appropriateanion to yield the platinum complex of the invention.

It is preferred to utilize a metal or other cation salt of the anionwhose by-product sulfate salt is insoluble in water to facilitateisolation of the platinum complex. For example, the use of the bariumsalt of the anion yields barium sulfate as a by-product which is readilyremovable from the reaction medium by filtration.

The reaction is preferably conducted in an aqueous medium at about roomtemperature for a time sufficient to drive the reaction to completion,generally from about 0.3 to about 0.5 hours.

The platinum complex may be isolated from the reaction medium byfiltering the by-product barium sulfate. The yellow filtrate isevaporated to dryness at 45°-50° C. under reduced pressure, e.g., usinga rotary evaporator. The yellow brown solid is then dried, e.g., over P₂O₅ under vacuum.

A reaction sequence for preparing the bis ascorbate complex, forexample, is depicted by the following equations wherein:

    L=DACH, and

    Asc=ascorbate

    K.sub.2 PtCl.sub.4 +L→LPtCl.sub.2 +2KCl

    LPtCl.sub.2 +Ag.sub.2 SO.sub.4 →LPtSO.sub.4 +2AgCl

    LPtSO.sub.4 +Ba(Asc).sub.2 →LPt(Asc).sub.2 +BaSO.sub.4

It is to be understood that is is within the scope of the method of thepresent invention to employ similar synthetic procedures to preparesuitable aryl, aralkyl or alkyl N-substituted iminodiacetato DACHplatinum complexes.

It is likewise apparent that by using similar synthetic procedures mixedisomer DACH,trans-R,R-DACH, trans-S,S-DACH or cis-DACH may be readilyprepared and used as the stable amine ligand for the platinumcoordination complexes of the present invention.

The method of the invention is illustrated by the following non-limitingexamples. The products of preparative examples 1-13, 22, 23 and 24 aresummarized in Table I.

                                      TABLE 1                                     __________________________________________________________________________    COMPOUND NO.                                                                            COMPOUND                EXAMPLE NO.                                 __________________________________________________________________________    1         cis-bis-dichloro(DACH)Pt(II)                                                                          1                                           2         sulfato(DACH)Pt(II)     2                                           3         cis-bis-ascorbato(DACH)Pt(II).1H.sub.2 O                                                              3                                           4         cis-bis-ascorbato(trans-R,R--DACH)Pt(II).3H.sub.2 O                                                   4                                           5         cis-bis-ascorbato(trans-S,S--DACH)Pt(II).2H.sub.2 O                                                   5                                           6         cis-bis-ascorbato(cis-DACH)Pt(II).5H.sub.2 O                                                          6                                           7         cis-bis-isoascorbato(DACH)Pt(II).3H.sub.2 O                                                           7                                           8         cis-bis-D-monosaccharato(DACH)Pt(II).3H.sub.2 O                                                       8                                           9         cis-bis-D-saccharato-1,4-lactone(DACH)Pt(II)                        10        cis-bis-shikimato(DACH)Pt(II).2H.sub.2 O                                                              10                                          11        iminodiacetato(DACH)Pt(II).2H.sub.2 O                                                                 11                                          12        DL-isocitratolactone(DACH)Pt(II).1H.sub.2 O                                                           12                                          13        cis-bis-isethionato(DACH)Pt(II).2H.sub.2 O                                                            13                                          14        cis-bis-2-aminoethylsulfato(DACH)Pt(II)                                                               13                                          15        cis-bis-L-azetidinecarboxylato(DACH)Pt(II).1H.sub.2 O                                                 13                                          16        cis-bis-L-prolinato(DACH)Pt(II)                                                                       13                                          17        cis-bis-L-hyroxyprolinato(DACH)Pt(II).1H.sub.2 O                                                      13                                          18        cis-bis-DL-pipecolinato(DACH)Pt(II).1H.sub.2 O                                                        13                                          19        furanedicarboxylato(DACH)Pt(II)                                                                       13                                          20        cyclopropane-1,1-dicarboxylato(DACH)Pt(II).H.sub.2 O                                                  13                                          21        isocitratomonoethylester(DACH)Pt(II).1.5H.sub.2 O                                                     13                                          22        Cis-bis-cyclohexanecarboxylato                                                                        24                                                    (DACH)Pt(II).1H.sub.2 O                                             23        1,1-cyclohexanediacetato(DACH)                                                                        24                                                    Pt(II).1H.sub.2 O                                                   24        Cis-bis-cyclohexenecarboxylato                                                                        24                                                    (DACH)Pt(II).1H.sub.2 O                                             25        Cis-bis-cyclopentanecarboxylato                                                                       24                                                    (DACH)Pt(II).1H.sub.2 O                                             26        Cis-bis-cyclopentenecarboxylato                                                                       24                                                    (DACH)Pt(II).2H.sub.2 O                                             27        trans-DL-1,2-cyclopentanedicar-                                                                       24                                                    boxylato(DACH)Pt(II)                                                28        N--Methyliminodiacetato(DACH)Pt                                                                       24                                                    (II).1H.sub.2 O                                                     29        Cis-bis-cyclopropanecarboxylato                                                                       24                                                    (DACH)Pt(II).1H.sub.2 O                                             30        Cis-bis-cyclobutanecarboxylato                                                                        24                                                    (DACH)Pt.1H.sub.2 O                                                 31        Cis-bis-ethanesulfonato(DACH)                                                                         24                                                    Pt(II).H.sub.2 O                                                    32        Cis-bis-glycinato(DACH)Pt(II).1H.sub.2 O                                                              24                                          33        Cis-bis-chloroethanesulfonato(DACH)                                                                   24                                                    Pt(II).1H.sub.  2 O                                                 34        Cis-bis-bicinato(DACH)Pt(II)                                                                          24                                          35        Iminodiacetato(trans-R,R--DACH)Pt(II).2H.sub.2 O                                                      23                                          36        Cis-bis-L-prolinato(trans-R,R--DACH)                                                                  22                                                    Pt(II).2H.sub.2 O                                                   37        N--Phenyliminodiacetato(DACH)Pt(II).2H.sub.2 O                                                        24                                          38        N--Benzyliminodiacetato(DACH)Pt(II)                                                                   24                                          39        N--(2-Hydroxyethyl)-iminodiacetato                                                                    24                                                    (DACH)Pt(II).2H.sub.2 O                                             40        trans-1,2-cyclopropanedicarboxylato                                                                   24                                                    (DACH)Pt(II)                                                        41        trans-1,2-cyclobutanedicarboxy-                                                                       24                                                    lato(DACH)Pt(II)                                                    42        N--(2-Acetamido)-iminodiacetato(DACH)                                                                 24                                                    Pt(II).1/2H.sub.2 O                                                 43        trans-1,2-cyclohexanedicarboxylato                                                                    24                                                    (DACH)Pt(II)                                                        __________________________________________________________________________

EXAMPLE 1 Cis-bis-dichloro(DACH)platinum(II)

To an aqueous filtered solution of K₂ PtCl₄ (3.5 g; 8.4 mmole in 50 mlof water) 0.9416 g (8.4 mmole) of DACH was added. The reaction mixturewas stirred at room temperature for 6-8 hours. A yellow solid wasprecipitated, filtered, washed with water, methanol and finally withacetone. The final product was dried under vacuum.

Yield=56%.

Cis-bis-dichloro(trans-1-DACH)platinum(II);cis-bis-dichloro(trans-d-DACH)platinum(II) andcis-bis-dichloro(cis-DACH)platinum(II) were prepared in an analogousmanner using stoichiometric amounts (ca. 1 mmole) of K₂ Ptcl₄ and therespective DACH isomers, i.e., trans-l, trans-d and cis-.

EXAMPLE 2 Sulfato(DACH)platinum(II)

Dichloro(DACH)platinum(II) (DACH being a mixture-, trans-l-, trans-d- orcis-isomer) (1.0 g; 2.6 mmole) was suspended in water (20 ml), and asolution of Ag₂ So₄ (0.75 g; 2.4 mmole) in water (150 ml) was added. Thereaction mixture was stirred at room temperature for 24 hours in thedark. The precipitated Agcl was filtered off, and the yellow filtratewas evaporated to dryness at 45°-50° C. under reduced pressure using arotary evaporator. A yellow-brown produce was obtained and dried over P₂O₅ under vacuum.

Yield: 90%.

EXAMPLE 3 Cis-bis-ascorbate(DACH)platinum(II).1H₂ O

Sulfato(DACH)platinum(II).H₂ O 0.846 g (2 mmole) was dissolved in water(50 ml) and barium ascorbate (0.974 g; 2 mmole in 30 ml of water) wasadded thereto. The reaction mixture was stirred ca. 20 minutes at roomtemperature. Barium sulfate precipitate was filtered off, and the yellowfiltrate was evaporated to dryness at 45°-50° C. under reduced pressureusing a rotary evaporator. A brown yellow product was obtained, whichwas then washed with acetone. The product was finally dried undervacuum.

Yield=90%. The analytical data for the product is set forth in Table II.

Platinum analysis-calculated for C₁₈ H₂₈ N₂ O₁₂ Pt.1H₂ O: Pt28.80%,Found: 28.72%.

EXAMPLE 4 Cis-bis-ascorbato(trans-R,R-DACH)platinum(II).3H₂ O

Sulfato(trans-R,R-DACH)platinum(II) 0.423 g (1 mmole) was dissolved inwater (20 ml) and a solution of barium ascorbate (0.478 g; 1 mmole in 10ml of water) was added thereto. The reaction mixture was stirred for 20minutes. Barium sulfate precipitate was filtered off, and the yellowfiltrate was evaporated to dryness at 45°-50° C. under reduced pressureusing a rotary evaporator. A brown yellow solid was obtained, which wasthen washed with acetone and dried in vacuo.

Yield=85%. The analytical data for the product is set forth in Table II.

EXAMPLE 5 Cis-bis-ascorbato(trans-S,S-DACH)platinum(II).2H₂ O

Sulfato(trans-SS-DACH)platinum(II) 0.423 g (1 mmole) was dissolved inwater (20 ml) and a solution of barium ascorbate (0.487; 1 mmole) in 10ml of water) was added thereto. The reaction mixture was stirred at roomtemperature for 20 minutes. Barium sulfate precipitate was filtered off,and the brown yellow filtrate was evaporated to dryness at 45°-50° C.under reduced pressure using a rotary evaporator. A yellow solid wasobtained which was then washed with acetone and dried under vacuum.

Yield=85%. The analytical data for the product is set forth in Table II.

EXAMPLE 6 Cis-bis-ascorbato(cis-DACH)platinum(II)

Sulfato(cis-DACH)platinum(II) 0.211 g (0.5 mmole) was dissolved in water(10 ml) and a solution of barium ascorbate (0.244 g; 0.5 mmole in 10 mlof water) was added thereto. The reaction mixture was stirred at roomtemperature for 20 minutes. Barium sulfate precipitate was filtered off,and the yellow filtrate was evaporated to dryness at 45°-50° C. underreduced pressure using a rotary evaporator. A brown yellow solid wasobtained, which was then washed with acetone and dried in vacuo.

Yield=80%. The analytical data for the product is set forth in Table II.

EXAMPLE 7 Cis-bis-isoascorbato(DACH)platinum(II).3H₂ O

Sulfato(DACH)platinum(II) 0.423 g (1 mmole) was dissolved in water (20ml) and a solution of barium isoascorbate (0.487 g; 1 mmole in 10 ml ofwater) was added thereto. The reaction mixture was stirred at roomtemperature for 20 minutes. Barium sulfate precipitate was filtered off,and the yellow filtrate was evaporated to dryness at 45°-50° C. underreduced pressure using a rotary evaporator. A brown yellow product wasobtained, which was then washed with acetone. The product was finallydried in vacuo.

Yield=85%. The analytical data for the product is set forth in Table II.

Platinum analysis-calculated for C₁₈ H₂₈ N₂ O₁₂ Pt.3H₂ O: Pt 27.34%.Found: Pt 27.56%.

EXAMPLE 8 Cis-bis-D-monosaccharato(DACH)platinum(II).3H₂ O

Sulfato(DACH)platinum(II) 1.04 g (2.47 mmole) was dissolved in water (50ml) and a solution of barium monosaccharate (1.372 g; 2.47 mmole in 80ml of water) was added thereto. The reaction mixture was stirred at roomtemperature for 20 minutes. Barium sulfate precipitate was filtered off,and the yellow filtrate was evaporated to dryness at 45°-50° C. underreduced pressure using a rotary evaporator. A brown yellow solid wasobtained, which was then washed with acetone and dried in vacuo.

Yield=89%. The analytical data for the product is set forth in Table II.

Platinum Analysis-calculated for C₁₈ H₃₂ N₂ O₁₆ Pt.3H₂ O: Pt 24.96%.Found: Pt 24.77%.

EXAMPLE 9 Cis-bis-D-saccharate-1,4-lactone(DACH)platinum(II)

Sulfato(DACH)platinum(II) 0.106 g was dissolved in 10 ml of water andbarium saccharate-1,4-lactone, prepared in situ by the addition ofBa(OH)₂.8H₂ O 0.075 g to an aqueous solution of D-saccharic acid 1,4lactone monohydrate 0.11 g was added thereto and the reaction mixturewas stirred for 30 minutes at room temperature. Barium sulfateprecipitate was filtered off and the yellow filtrate was evaporated todryness at 45°-50° C. under reduced pressure using a rotary evaporator.A brown yellow solid was obtained, which was then washed with methanoland acetone. The product was finally dried in vacuo.

Yield=82%. The analytical data for the product is set forth in Table II.

EXAMPLE 10 Cis-bis-shikimato(DACH)platinum(II)

Sulfato(DACH)platinum(II) 0.423 g (1 mmole) was dissolved in water (20ml) and a solution of barium shikimate (0.483 g; 1 mmole in 50 ml ofwater) was added thereto. The reaction mixture was stirred at roomtemperature for 20 minutes. Barium sulfate precipitate was filtered off,and the yellow filtrate was evaporated to dryness at 45°-50° C. underreduced pressure using a rotary evaporator. A brown yellow solid wasobtained, which was then washed with acetone and dried in vacuo.

Yield=80%. The analytical data for the product is set forth in Table II.

Platinum Analysis-Calculated for C₂₀ H₃₂ N₂ O₁₀ Pt.2H₂ O Pt 28.20%.Found: Pt 28.76%.

EXAMPLE 11 Iminodiacetato(DACH)platinum(II)

Sulfato(DACH)platinum(II) 1.04 g (2.47 mmole) was dissolved in water (50ml) and a solution of barium iminodiacetate (0.663 g; 2.57 mmole in 50ml of water) was added thereto. The reaction mixture was stirred at roomtemperature for 20 minutes. Barium sulfate precipitate was filtered off,and the yellow filtrate was evaporated to dryness at 45°-50° C. underreduced pressure using a rotary evaporator. A brown yellow solid wasobtained, which was then washed with acetone and dried in vacuo.

Yield=79%. The analytical data for the product is set forth in Table II.

EXAMPLE 12 DL-Isocitratolactone(DACH)platinum(II)

Sulfato(DACH)platinum(II) 0.106 g (0.25 mmole) was dissolved in water(10 ml) and a solution of barium isocitratolactone (0.766 g; 0.25 mmolein 20 ml of water) was added thereto. The reaction mixture was stirredat room temperature for 20 minutes. Barium sulfate precipitate wasfiltered off, and the yellow filtrate was evaporated to dryness at45°-50° C. under reduced pressure using a rotary evaporator. A brownyellow solid was obtained, which was then washed with acetone and driedin vacuo.

Yield=75%. The analytical data for the product is set forth in Table II.

The other complexes of the invention, i.e., bis-isethionato,bis-2-aminoethylsulfato, bis-azetidinecarboxylato, bis-prolinato,bis-hydroxyprolinato, bis-pipecolinato, and isocitratomonoethyl esterwere prepared in an analogous manner to the methods of Example 9, usingstoichiometric amounts (ca. 1 mmole) sulfato(DACH)-platinum(II) and therespective barium salts, i.e., isethionate, 2-aminoethylsulfate,azetidinecarboxylate, proline, hydroxyproline, pipecolinate, andisocitratemonoethyl ester.

It will be understood by those skilled in the art that the variousisomeric DACH (i.e., trans-S,S-, trans-R,R-, cis-) can be preparedaccording to the methods of the above examples employing the appropriateDACH isomer. The analytical data for the compounds prepared in Examples1-13 are set forth in Table II.

                  TABLE II                                                        ______________________________________                                                ANALYTICAL DATA                                                       COMPOUND  FOUND (%)       CALCULATED (%)                                      NO.       C       H      N      C    H    N                                   ______________________________________                                         3        32.15   4.32   3.85   31.90                                                                              4.43 4.13                                 4        30.01   4.53   3.70   30.28                                                                              4.76 3.92                                 5        31.28   4.38   3.93   31.07                                                                              4.60 4.03                                 6        28.94   4.01   3.73   28.83                                                                              5.07 3.74                                 7        30.25   4.19   3.93   30.28                                                                              4.76 3.92                                 8        27.16   4.23   3.23   27.64                                                                              4.86 3.58                                 9        29.66   4.15   3.53   29.70                                                                              3.85 3.85                                10        34.60   5.11   3.75   34.72                                                                              5.20 4.05                                11        25.35   4.83   8.57   25.20                                                                              4.83 8.82                                12        28.65   4.13   5.42   28.85                                                                              4.00 5.61                                13        19.62   4.16   4.19   20.16                                                                              4.70 4.70                                14        20.28   4.62   8.99   20.36                                                                              4.41 9.50                                15        31.98   5.20   10.48  31.86                                                                              5.31 10.62                               16        35.63   5.77   9.87   35.73                                                                              5.58 10.42                               17        32.75   5.57   9.39   32.69                                                                              5.11 9.53                                18        37.30   6.21   9.46   37.03                                                                              6.17 9.70                                19        28.84   3.53   5.33   28.80                                                                              4.00 5.60                                20        29.37   4.44   5.50   28.94                                                                              4.60 6.14                                21        30.10   4.46   5.32   30.32                                                                              4.87 5.05                                ______________________________________                                    

The in vitro anti-tumor activities of the complexes of the invention areillustrated by the following examples:

EXAMPLE 14

Wild type L1210 leukemic cells were grown as a suspension culture inMcCoy's 5A medium supplemented with 10% horse serum, glutamine,streptomycin and penicillin at 37° C., 95% relative humidity and 5% CO₂.Four ml of cell suspension (10⁵ cells/ml) are added to culture tubes andthe appropriate concentration (0.01, 0.1, 1 or 10 μg/ml finalconcentration) of drug added to the culture tubes. After 72 hours ofincubation, the cell concentration of control and experimental culturesare determined with the aid of a Coulter Counter® Model ZB_(f) and thepercent inhibition calculated.

    ______________________________________                                        COMPOUND NUMBER    ID.sub.50 (μg/ml)                                       ______________________________________                                         3                 5.0                                                         4                 1.9                                                         5                 4.4                                                         6                 4.0                                                         7                 4.1                                                         8                 2.8                                                         9                 3.0                                                        10                 2.5                                                        11                 4.2                                                        12                 1.0                                                        13                  0.43                                                      14                 4.3                                                        15                 3.6                                                        16                 4.0                                                        17                 2.7                                                        18                  0.44                                                      19                 1.0                                                        20                  0.41                                                      21                 2.0                                                        ______________________________________                                    

The lack of cross-resistance of complexes of the invention tocisdiamminedichloroplatinum(II) is illustrated below:

EXAMPLE 15

L1210 leukemia cells (L1210/PDD) which are more than 50 fold resistantto cisdiamminedichloroplatinum(II) were grown as suspension cultures inMcCoy's 5A supplemented with 10% horse serum, glutamine, penicillin andstreptomycin at 37° C., 95% relative humidity and 5% CO₂. Four ml ofcell suspension were added to culture tubes and the appropriateconcentration (0.01, 0.1, 1 or 10 μg/ml final drug concentration) wasadded. After 96 hours the cell concentration of control and experimentalcultures were calculated with the aid of a Coulter Counter® Model ZB_(f)and the percent inhibition calculated.

    ______________________________________                                                        ID.sub.50 (μg/ml)                                          COMPOUND NUMBER   L1210/0  L1210/PDD                                          ______________________________________                                        3                 5.0      2.6                                                4                 1.9      0.4                                                5                 4.4      2.3                                                8                 2.8      0.9                                                9                 3.0      0.6                                                10                2.5      1.2                                                11                4.2      1.6                                                cisdiamminedichloro-                                                                            0.1      5.5                                                platinum(II)                                                                  ______________________________________                                    

The anti-tumor activities of the complexes of the invention areillustrated by the following example:

EXAMPLE 16

BDF₁ mice were inoculated intraperitoneally with 10⁶ L1210 cells. About24 hours after inoculation of the cells, the mice were injectedintraperitoneally with varying dosages of complexes of the presentinvention. Six mice were used for each dosage level in each experimentwith an equal number of control mice inoculated with 10⁶ L1210 cells andleft untreated with a given complex. The results [%T/C=(survival time oftreated animals/survival time of control animals)×100] are set forthbelow. Long term survival signifies that animals were alive 60 daysafter inoculation with L1210 cells.

    ______________________________________                                                                           Long Term                                  COMPOUND NUMBER                                                                              DOSE(mg/kg) % T/C   Survivors                                  ______________________________________                                        3              50          125     --                                                        60          163     --                                                        75          143     --                                                        90          145     --                                                        100         Toxic   --                                         4              25          128     --                                                        50          184     1/6                                        5              25          136     --                                                        50          Toxic   --                                         6              50          Toxic   --                                                        100         Toxic   --                                         7              25          132     --                                                        50          136     --                                                        100          196*   1/6                                        *2/6 animals died of apparent drug toxicity                                   8              12.5        120     --                                                        25          129     --                                                        50          156     --                                                        100         151     --                                                        200         Toxic   --                                         9              12.5        127     --                                                        25          138     --                                                        50          156     --                                                        100         Toxic   --                                         10             50          140     --                                                        100         217     2/6                                        11             50          163     --                                                        100          109*   --                                         12             25          133     --                                                        50          145     --                                                        100         Toxic   --                                         *Apparent Toxicity                                                            13             5           153     --                                                        10          180     --                                                        20           140*   1/6                                                       50          Toxic   --                                         *2/6 animals died of apparent drug toxicity                                   14             6.25                                                                          12.5        In                                                                25          Progress                                                          50                                                             15             12.5        157     --                                                        25          148     --                                                        50          161     --                                                        100         Toxic   --                                         16             12.5        144     --                                                        25          165     --                                                        50          165     --                                                        100          162*   --                                         *1 animal died from apparent toxicity                                         17             25          160     --                                                        50          170     --                                                        100         Toxic   --                                         18             12.5        145     --                                                        25          180     --                                                        50          Toxic   --                                         19             6.25        143     --                                                        12.5        136     --                                                        25          136     --                                                        50          Toxic   --                                         ______________________________________                                    

EXAMPLE 17

The procedure of Example 16 was repeated except that the treated animalswere injected with multiple doses of the complex as indicated below:

    ______________________________________                                        COMPOUND  DOSE     Day of            Long Term                                NUMBER    (mg/kg)  Administration                                                                            % T/C Survivors                                ______________________________________                                         3        25       1,5,9       176   --                                                 10       1,5,9       123   --                                                 20       1,5,9       196   1/6                                                30       1,5,9       257   1/6                                                30       1,5,9,13    273   1/6                                                2.5      1-9         113   --                                                 5        1-9         142   --                                                 10       1-9         184   --                                                 20       1-9         239   1/6                                       4        25       1,5,9       218   --                                                 50       1,5,9       144   --                                        7        12.5     1,5,9       151   --                                                 25       1,5,9       179   --                                                 50       1,5,9       212   --                                        8        25       1,5,9       206   --                                                 50       1,5,9       225   1/6                                      10        12.5     1,5,9       139   --                                                 25       1,5,9       149   --                                                 50       1,5,9       222   1/6                                      11        25       1,5,9       199   --                                                 50       1,5,9       220   2/6                                      12        25       1,5,9       219   --                                                 50       1,5,9       165   --                                       ______________________________________                                    

EXAMPLE 18

The anti-tumor activity of compound number 3 was evaluated against cellssensitive to (L1210/0) and resistant to (L1210/PDD) the standardplatinum complex cis-diamminedichloroplatinum(II).

    ______________________________________                                        DOSE(mg/kg)                                                                             SCHEDULE     % T/C   SURVIVORS                                      ______________________________________                                        L1219/PDD                                                                     6.25      1,5,9        115     --                                             12.5      1,5,9        124     --                                             25        1,5,9        135     --                                             50        1,5,9        223     3/10                                           100       1,5,9         172*                                                  L1210/0                                                                       6.25      1,5,9        117     --                                             12.5      1,5,9        135     --                                             25        1,5,9        181     2/10                                           50        1,5,9        247     1/10                                           100       1,5,9        104     --                                             ______________________________________                                         *Toxicity apparent as excessive loss of weight                           

The acute toxicity data obtained with selected complexes of theinvention are set forth below:

EXAMPLE 19

Male albino mice were administered a single intraperitoneal injection ofthe appropriate test compound and were observed daily for signs oftoxicity and survival. Fourteen days after treatment all surviving micewere sacrified and the LD₁₀, LD₅₀ and LD₉₀ were calculated.

    ______________________________________                                                                    DEATHS/                                           COMPOUND NUMBER DOSE (mg/kg)                                                                              TREATED                                           ______________________________________                                         3              110         1/6                                                               125         2/6                                                               140         4/6                                                               155         6/6                                                               175         6/6                                               Calculated LD.sub.10 108 mg/kg                                                Calculated LD.sub.50 125 mg/kg                                                Calculated LD.sub.90 150 mg/kg                                                 5               60         0/6                                                                80         2/6                                                               100         5/6                                                               125         6/6                                                               160         5/6                                               Calculated LD.sub.10  70 mg/kg                                                Calculated LD.sub.50  90 mg/kg                                                Calculated LD.sub.90 125 mg/kg                                                 8              100         1/6                                                               125         1/6                                                               158         4/6                                                               200         3/6                                                               250         6/6                                               Calculated LD.sub.10 115 mg/kg                                                Calculated LD.sub.50 155 mg/kg                                                Calculated LD.sub.90 220 mg/kg                                                 9               85         0/6                                                               100         0/6                                                               125         3/6                                                               158         5/6                                                               200         4/6                                               Calculated LD.sub.10 100 mg/kg                                                Calculated LD.sub.50 140 mg/kg                                                Calculated LD.sub.90 185 mg/kg                                                10               50         0/6                                                               100         1/6                                                               125         3/6                                                               160         5/6                                                               200         3/6                                               Calculated LD.sub.10  85 mg/kg                                                Calculated LD.sub.50 130 mg/kg                                                Calculated LD.sub.90 205 mg/kg                                                11               85         1/6                                                               100         3/6                                                               125         5/6                                                               158         4/6                                                               200         6/6                                               Calculated LD.sub.10  80 mg/kg                                                Calculated LD.sub.50 115 mg/kg                                                Calculated LD.sub.90 155 mg/kg                                                ______________________________________                                    

The potential nephrotoxicity of selected complexes of the invention areset forth below:

EXAMPLE 20

Male albino mice were administered a single intraperitoneal injection ofeither the calculated LD₁₀ or LD₅₀ of the test compound. Blood was thenobtained by retroorbital puncture 96 hours after treatment fordetermination of blood urea nitroben (BUN) levels (a standard method ofscreening compounds for potential renal toxicity).

    ______________________________________                                                         RELATIVE   BUN                                               COMPOUND NUMBER  DOSE       (mg/100 ml)                                       ______________________________________                                        3                LD.sub.10  25 ± 6                                                          LD.sub.50  23 ± 6                                         5                LD.sub.10  31 ± 3                                                          LD.sub.50  38 ± 9                                         8                LD.sub.10  31 ± 8                                                          LD.sub.50   35 ± 12                                       9                LD.sub.10  38 ± 8                                                          LD.sub.50   50 ± 15                                       10               LD.sub.10  40 ± 7                                                          LD.sub.50  39 ± 5                                         11               LD.sub.10   36 ± 12                                                        LD.sub.50   38 ± 10                                       0.09% NaCl       --         32 ± 2                                         cis diamminedichloro                                                                           LD.sub.10   53 ± 19                                       platinum(II)     LD.sub.50   67 ± 10                                       ______________________________________                                    

EXAMPLE 21 Cis-bis-2-aminoethanesulfonato(DACH)platinum(II)

Sulfato(DACH)platinum(II), 0.211 g, was dissolved in 10 of water andbarium-2-amino-ethanesulfonate, prepared in situ by the addition ofBa(OH)₂.8H₂ O, 0.15 g, to an aqueous solution of 2-aminoethanesulfonicacid, 0.125 g, was added thereto and the reaction mixture was stirredfor 30 minutes at room temperature. Barium sulfate precipitate wasfiltered off and the yellow filtrate was evaporated to dryness at45°-50° C. under reduced pressure using a rotary evaporator. A brownyellow solid was obtained which was then washed with methanol andacetone. The product was obtained which was then washed with methanoland acetone. The product was finally dried in vacuo.

Yield=80%.

The analytical data for the product are set forth in Table III.

EXAMPLE 22 Cis-bis-L-prolinato(trans-R,R-DACH)platinum(II)

Sulfato (trans-R,R-DACH)platinum(II) (0.11 g) was dissolved in 20 ml ofwater and the barium salt of L-proline, prepared in situ by the additionof Ba(OH)₂.8H₂ O (0.150 g) to an aqueous solution of L-proline (0.115 g)was added thereto and the reaction mixture was stirred for 20-30 minutesat room temperature. Barium sulfate precipitate was filtered off and theyellow filtrate was evaporated to dryness at 45°-50° C. under reducedpressure using a rotary evaporator. A yellowish-white solid was obtainedwhich was then washed with methanol and acetone. The product was finallydried in vacuo.

Yield=75%.

The analytical data for the product are set forth in Table III.

EXAMPLE 23 Iminodiacetato(trans-R,R-DACH)platinum(II)2H₂ O

Sulfato(trans-R,R-DACH)platinum(II), 0.423 g, was dissolved in 50 ml ofwater and barium iminodiacetate prepared in situ by the addition ofBa(OH)₂.8H₂ O, 0.3 g, to an aqueous solution of iminodiacetic acid,0.133 g in 100 ml water was added thereto and the reaction mixture wasstirred for 20-30 minutes at room temperature. Barium sulfateprecipitate was filtered off and the yellow filtrate was evaporated todryness at 45°-50° C. under reduced pressure using a rotary evaporator.A yellowish-white solid was obtained which was then washed with acetone.The product was then dried in vacuo. Yield=70%.

The analytical data for the product are set forth in Table III.

EXAMPLE 24 Cis-bis-cyclopropanecarboxylato(DACH)platinum(II)

Sulfato(DACH)platinum(II), 0.423 g (1 mmole), was dissolved in water (20ml) and barium cyclopropanecarboxylate, prepared in situ by the additionof Ba(OH)₂.8H₂ O (0.30 g) to an aqueous solution ofcyclopropanecarboxylic acid (0.172 g) (2 mmole), was added thereto andthe reaction mixture was stirred for 20-30 minutes at room temperature.Barium sulfate precipitate was filtered off and the yellow filtrate wasevaporated to dryness at 45°-50° C. under reduced pressure using arotary evaporator. A brown yellow solid was obtained, which was purifiedfrom methanol. The product was finally dried in vacuo. Yield=70%. Theanalytical data for the products are set forth in Table III.

Other complexes of the invention, i.e. bis-cyclobutanecarboxylate,bis-cyclopentanecarboxylato, bis-cyclopentenecarboxylato,bis-cyclohexanecarboxylato, bis-cyclohexenecarboxylato,cyclopropane-1,1-dicarboxylato, trans-DL-1,2-cyclopentanecarboxylato,cyclohexane-1,1-diacetato, bicinato, chloroethanesulfonato,N-(2-hydroxyethyl)-iminodiacetato, N-(2-acetamido)-iminodiacetato,N-methyliminodiacetato, N-phenyl-iminodiacetato,N-benzyl-iminodiacetato, 3,4-furanedicarboxylato, trans-1,2-cyclopropanedicarboxylato, trans-1,2-cyclobutanedicarboxylato,trans-1,2-cyclopentane dicarboxylato andtrans-1,2-cyclohexanedicarboxylato were prepared in an analogous mannerto the above mentioned method using stoichiometric amounts (ca/1 mmole)sulfato (DACH) platinum (II), and the respective barium salts (preparedin situ) i.e. cyclobutanecarboxylate, cyclopentanecarboxylate,cyclopentenecarboxylate, cyclohexanecarboxylate, cyclohexenecarboxylate,cyclopropane-1,1-dicarboxylate, trans-DL-1, 2-cyclopentanedicarboxylate,cyclohexane-1,1-diacetate, bicinate, chloroethanesulfonate,N-(2-hydroxy-ethyl)iminodiacetate, N-(2-acetamido)iminodiacetate,N-methyliminoacetate, N-phenyliminoacetate, N-benzyliminodacetate,3,4-furanedicarboxylate, trans-1,2-cyclopropanedicarboxylate,trans-1,2-cyclobutanedicarboxylate, trans-1,2-cyclopentanedicarboxylateand trans-1, 2-cyclohexanedicarboxylate.

                  TABLE III                                                       ______________________________________                                        Analytical Data                                                               COMPOUND   Found (%)     Calculated (%)                                       NO.        C      H      N     C     H    N                                   ______________________________________                                        22         41.23  6.93   5.46  41.30 6.54 4.82                                23         36.58  5.75   5.03  36.55 5.71 5.33                                24         41.20  5.47   4.64  41.56 5.89 4.85                                25         38.82  5.29   5.04  39.06 6.14 5.06                                26         37.77  5.52   4.97  37.95 5.62 4.92                                27         33.43  4.58   5.45  33.50 4.72 6.01                                28         27.95  5.16   8.58  27.96 4.87 8.89                                29         33.40  5.31   5.48  33.79 5.23 5.63                                30         36.61  5.72   5.21  36.55 5.71 5.33                                31         20.77  5.05   9.51  20.86 4.86 9.73                                32         25.31  5.32   11.64 25.25 5.05 11.78                               33         18.26  3.91   3.78  18.46 3.69 4.30                                34         33.98  5.43   8.33  34.00 5.98 8.81                                35         25.14  4.37   8.59  25.20 4.83 8.82                                36         33.41  5.76   9.47  33.50 5.93 9.77                                37         34.65  4.94   7.99  34.77 4.89 7.60                                38         38.50  5.20   7.31  38.47 4.71 7.92                                39         27.96  5.15   7.62  27.69 5.19 8.07                                40         27.96  4.43   5.57  27.90 4.65 5.92                                41         31.64  4.83   5.85  31.93 4.43 6.21                                42         28.34  5.22   10.47 28.45 4.54 11.00                               43         33.86  5.62   5.40  33.12 5.12 5.52                                ______________________________________                                    

In Vitro Cytotoxicity

The following compounds were tested for in vitro cytotoxicity accordingto the protocol described in Example 14.

    ______________________________________                                        Compound No.   ID.sub.50 (μg/ml)                                           ______________________________________                                        22             0.5                                                            23             0.6                                                            24             1.0                                                            25             0.3                                                            26             1.3                                                            27             0.4                                                            28             1.6                                                            29             0.3                                                            30             0.4                                                            31             3.1                                                            32             2.5                                                            33             0.3                                                            34             1.2                                                            35             3.0                                                            36             0.8                                                            37             1.0                                                            38             2.3                                                            39             3.0                                                            40             0.4                                                            41             0.5                                                            42             0.7                                                            ______________________________________                                    

In Vivo Efficacy Studies--Single Dose

The following compounds were tested for in vivo oncolytic activityfollowing a single i.p. injection of the drug according to the protocoldescribed in Example 16.

    ______________________________________                                        Compound No.                                                                              Dose (mg/kg)   % T/C   LTS                                        ______________________________________                                        25          50             163     --                                                     25             178     --                                                     12.5           161     --                                         27          50             183     --                                                     25             159     --                                                     12.5           158                                                28          50             Toxic   --                                                     25             185     --                                                     12.5           161     --                                         29          50             199     1/6                                                    25             176     --                                                     12.5           252     1/6                                        30          50             145     --                                                     25             154     --                                                     12.5           149     --                                         26          50             157     --                                                     25             158     --                                                     12.5           185     --                                         31          50             153     --                                                     25             134     --                                                     12.5           109     --                                         32          50             158     --                                                     25             131     --                                                     12.5           128     --                                         33          50             Toxic   --                                                     25             144     --                                                     12.5           188     --                                         34          50             160     --                                                     25             151     --                                                     12.5           165     --                                         36          50             149     --                                                     25             212     1/6                                                    12.5           179     --                                         37          50             108     --                                                     25             156     --                                                     12.5           172     --                                         38          50             158     --                                                     25             170     --                                                     12.5           123     --                                         22          100            170     --                                                     50             140     --                                         24          100            105     --                                                     50             165     --                                                     25             132     --                                         ______________________________________                                    

In Vivo Efficacy Studies--Multiple Dose

The following complexes were tested in vivo oncolytic activity following3 i.p. injections (days 1, 5, 9) according to the protocol described inExamples 16 and 17.

    ______________________________________                                        Compound No.                                                                              Dose (mg/kg)   % T/C   LTS                                        ______________________________________                                        25          25             253     --                                                     12.5           246     --                                                     6.25           202     --                                         26          25             300     1/6                                                    12.5           356     1/6                                                    6.25           189     --                                         31          100            295     2/6                                                    50             198     1/6                                        37          25             242     1/6                                                    12.5           298     5/6                                                    6.25           246     3/6                                        38          25             240     2/6                                                    12.5           287     1/6                                                    6.25           277     --                                         ______________________________________                                    

T/C calculated for 30 day observation period. Long term survivor datarepresents survivors/treated 50 days after treatment.

EXAMPLE 25

Mixed isomer DACH-Pt-(II)-L-complexes listed in Table IV below wereprepared in an analogous manner to the methods of Example 8, using thestoichiometric amounts (ca. 1 mmole) sulfato-(DACH)-platinum (II) andthe appropriate barium salt.

                  TABLE IV                                                        ______________________________________                                        Mixed isomer DACH-Pt-(II)-L-Complexes                                         Complex (L =)         Identifier No.                                          ______________________________________                                        bis-ascorbato          1                                                      bis-isoascorbato       2                                                      bis-monosaccharato     3                                                      bis-shikimato          4                                                      bis-prolinato          5                                                      bis-aminoethylsulfato  6                                                      bis-saccharato-1,4-lactone                                                                           7                                                      mono-furanedicarboxylato                                                                             8                                                      mono-isocitratomonoethylester                                                                        9                                                      mono-iminodiacetato   10                                                      mono-N--methyliminodiacetato                                                                        11                                                      mono-N--hydroxyethyliminodiacetato                                                                  12                                                      mono-N--(2-acetamido)iminodiacetato                                                                 13                                                      mono-N--phenyliminodiacetato                                                                        14                                                      mono-N--benzyliminodiacetato                                                                        15                                                      ______________________________________                                    

EXAMPLE 26

Trans-R,R-DACH-Pt(II) complexes listed in Table V below were prepared ina manner analogous to the method of Example 25 usingsulfato-(trans-R,R-DACH)-platinum(II) and the appropriate barium salt.

                  TABLE V                                                         ______________________________________                                        Trans-R,R-DACH-Pt(II)-L-Complexes                                             Complex (L=)          Identifier No.                                          ______________________________________                                        Mono-iminodiacetato   10a                                                     mono-N--methyliminodiacetato                                                                        11a                                                     mono-N--hydroxyethyliminodiacetato                                                                  12a                                                     mono-N--phenyliminodiacetato                                                                        14a                                                     mono-N--benzyliminodiacetato                                                                        15a                                                     ______________________________________                                    

The analytical data for the products of Examples 25 and 26 are set forthin Table VI below:

                  TABLE VI                                                        ______________________________________                                        ANALYTICAL DATA                                                                        Observed (%)                                                                              Calculated (%)                                           Identifier No.                                                                           C      H      N     C     H    N                                   ______________________________________                                        1          32.15  4.32   3.85  31.90 4.43 4.13                                2          30.25  4.19   3.93  30.28 4.16 3.92                                3          27.16  4.23   3.23  27.64 4.56 3.58                                4          34.60  5.11   3.75  34.72 5.20 4.05                                5          35.63  5.77   9.87  35.73 5.58  10.12                              6          20.28  4.62   8.99  20.36 4.41 9.30                                7          29.66  4.15   3.53  29.70 3.85 3.85                                8          28.84  3.53   5.33  28.80 4.00 5.60                                9          30.10  4.46   5.32  30.32 4.87 5.05                                10         25.35  4.83   8.57  25.20 4.83 8.82                                10a        25.27  4.79   8.63  25.20 4.83 8.82                                11         27.95  5.16   8.58  27.96 4.87 8.89                                11a        28.00  5.05   8.67  27.96 4.87 8.89                                12         27.96  5.15   7.62  27.69 5.19 8.07                                12a        27.75  5.22   8.00  27.69 5.19 8.07                                13         28.34  5.22    10.74                                                                              28.45 5.54  11.00                              13a        28.39  5.32    10.85                                                                              28.45 5.54  11.00                              14         34.65  4.94   7.99  34.77 4.89 7.60                                14a        34.69  4.88   7.84  34.77 4.89 7.60                                15         38.50  5.20   7.31  38.47 4.71 7.82                                15a        38.45  5.16   7.43  38.47 4.71 7.82                                ______________________________________                                    

In Vitro Cytotoxicity

The complexes listed in Example 25 and 26 were tested for in vitrocytoxicity according to the protocol described in Example 14. Theresults are shown in Tables VII and VIII below.

                  TABLE VII                                                       ______________________________________                                        Cytoxicity Data of DACH Pt-L Complexes                                                     ID.sub.50 (μg/ml)                                                                        Resistance                                         Complex (L=)   L1210/0  L1210/DDP  Factor                                     ______________________________________                                        bis-ascorbato  5.0      5.0        1.0                                        bis-isoascorbato                                                                             4.1      3.8        0.9                                        bis-monosaccharato                                                                           2.8      0.9        0.3                                        bis-shikimato  2.5      1.2        0.5                                        bis-prolinato  4.0      2.5        0.6                                        bis-aminoethylsulfato                                                                        4.3      3.7        0.9                                        bis-saccharato-                                                                              3.0      0.6        0.2                                        1,4-lactone                                                                   mono-furanedicarboxylato                                                                     1.0      0.9        0.9                                        mono-isocitratomono-                                                                         2.0      1.9        0.9                                        ethylester                                                                    mono-iminodiacetato                                                                          4.2      1.6        0.4                                        mono-N--methyliminodia-                                                                      1.6      1.3        0.8                                        cetato                                                                        mono-N--hydroxyethly-                                                                        0.7      0.9        1.3                                        iminodiacetato                                                                mono-N--(2-acetamido)-                                                                       3.0      1.8        0.6                                        iminodiacetato                                                                mono-N--phenylimino-                                                                         2.3      2.6        1.1                                        diacetato                                                                     mono-N--benzylimino-                                                                         1.0      0.8        0.8                                        diacetato                                                                     DDP            0.1      5.5        55                                         ______________________________________                                    

                  TABLE VIII                                                      ______________________________________                                        Cytotoxicity Data for the trans-R,R-DACH Pt-L Complexes                                     ID.sub.50 (μg/ml)                                                                           Resistance                                     Complex (L = )                                                                              L1210/0   L1210/DDP  Factor                                     ______________________________________                                        mono-iminodiacetato                                                           mono-N--methylimino-                                                                        0.8       1.9        2.4                                        diacetato                                                                     mono-N--hydroxyethyl-                                                                       1.4       1.8        1.3                                        iminodiacetato                                                                mono-N--phenylimino-                                                                        0.7       0.6        0.8                                        diacetato                                                                     mono-N--benzylimino-                                                                        1.0       2.4        2.4                                        diacetato                                                                     DDP           0.1       5.5        55                                         ______________________________________                                    

In Vivo Efficacy vs. L1210/0

BDF₁ mice were innoculated intraperitoreally with 10⁶ L1210 leukemiacells and treatment was begun on the next day (day 1). Two treatmentschedules, i.e. single i.p. injection of the drug and i.p. injections ondays 1, 5 and 9 according to the protocol described in Examples 16 and17 were used.

The data appears below in Table IX and X.

                  TABLE IX                                                        ______________________________________                                        In Vivo Efficacy of DACH Iminodiacetato Complexes                             Administered as Single i.p. Injection                                                        Maximal Effective                                              Complex (L =)  Dose (mg/Kg)  % T/C                                            ______________________________________                                        H.sub.3        50            163                                              CH.sub.3       25            180                                              C.sub.2 H.sub.5 OH                                                                           25            180                                              C.sub.6 H.sub.5                                                                              12.5          172                                              CH.sub.2 --C.sub.6 H.sub.5                                                                   25            170                                              DDP            9             150                                              ______________________________________                                         ##STR5##                                                                      .sup.(b) DDP = diamminedichloroplatinum II                               

                  TABLE X                                                         ______________________________________                                        In Vivo Efficacy of DACH-Pt-Iminodiacetato Complexes                          Administered i.p. on Days 1, 5 and 9                                                     Maximal Effective      Long Term.sup.a                             Complex (L=)                                                                             Dose (mg/kg)   % T/C   Survivors                                   ______________________________________                                        H.sub.3    50             220     2/6                                         CH.sub.3   12.5           550     5/6                                         C.sub.2 H.sub.5 OH                                                                       25             450     4/6                                         C.sub.6 H.sub.5                                                                          12.5           537     4/6                                         CH.sub.2 --C.sub.6 H.sub.5                                                               12.5           397     2/6                                         DDP        5              210     1/6                                         ______________________________________                                         .sup.a Long Term Survivors = animals alive 60 days after tumor inoculatio     with no visible signs of tumor at sacrifice.                             

Table Xi below shows the in vivo efficacy results obtained withtrans-R,R-DACH Pt-iminodiacetato complexes.

                  TABLE XI                                                        ______________________________________                                        In Vivo Efficacy of trans-R,R-DACH Pt-Iminodiacetato                          Complexes Administered i.p. on Days 1, 5 and 9                                           Maximal Effective      Long Term                                   Complex (L=)                                                                             Dose (mg/kg)   % T/C   Survivors                                   ______________________________________                                        H          25             437     2/6                                         CH.sub.3   6.25           700     6/6                                         C.sub.2 H.sub.5 OH                                                                       6.25           384     2/6                                         C.sub.6 H.sub.5                                                                          6.25           578     4/6                                         CH.sub.2 --C.sub.6 H.sub.5                                                               6.25           620     4/6                                         DDP        5              220     1/6                                         ______________________________________                                    

The data show that the trans-R,R-DACH complexes are more potent than themixed isomer DACH complexes and are much more effective than the DDP.

MELANOTIC MELANOMA TEST

The animals used were BDF₁ mice, all of the same sex, weighing a minimumof 18 g. and all within a 4 g. weight range. There were 6 animals pertest group. The mice were inoculated intraperitoneally with 10⁶ viableB16 cells (day 0). The test compounds were administeredintraperitoneally on days 1, 5 and 9 at various doses. The animals wereweighed and survivors were recorded on a regular basis for 60 days. Themedian survival time and the ratio of survival time for treated(T)/control (C) animals were calculated. The positive control compoundwas DDP given intraperitoneally at 5 mg/kg. The criterion for efficacyis T/C×100≧125%. The results of the tests appear in Table XII below.

                  TABLE XII                                                       ______________________________________                                        Efficacy of DACH-Pt-Iminodiacetato Complexes Against                          i.p. Inoculated B16 Melanoma                                                             Maximal Effective      Long Term                                   Complex (L = )                                                                           Dose (mg/kg)   % T/C   Survivors                                   ______________________________________                                        CH.sub.3 (t)                                                                             25             210     2/6                                         CH.sub.3 (m)                                                                             25             205     0/6                                         C.sub.2 H.sub.5 OH(m)                                                                    25             196     2/6                                         C.sub.2 H.sub.5 OH(t)                                                                    25             265     4/6                                         C.sub.6 H.sub.5 (t)                                                                      25             160     3/6                                         C.sub.6 H.sub.5 (m)                                                                      25             215     0/6                                         CH.sub.2 --C.sub.6 H.sub.5 (t)                                                           12.5           252     3/6                                         CH.sub.2 --C.sub.6 H.sub.5 (m)                                                           12.5           207     1/6                                         DDP        5              172     1/6                                         ______________________________________                                         (m) = mixed isomer DACH                                                       (t) = transR,R-DACH                                                      

These data show that at least three of the complexes tested were moreeffective than DDP against B16 and that all of the remaining complexeswere at least as effective as DDP against B16.

TOXOCOLOGICAL STUDIES

The LD₁₀ and LD₅₀ values for a single intraperitoneal injection of thetest compounds are shown in Table XIII below.

                  TABLE XIII                                                      ______________________________________                                        Acute Lethality Data for Mixed Isomer DACH Pt.                                Iminodiacetato Complexes                                                             LD.sub.10                                                                           LD.sub.50                                                                             LD.sub.90                                                                             RUN (mg/100 ml)                                         (mg/kg)       (mean + 1 S.D.)                                          ______________________________________                                        H        53      107     169   23 ± 4                                      CH.sub.3 49      92      170   22 ± 3                                      C.sub.2 H.sub.5 OH                                                                     63      150     301   18 ± 2                                      C.sub.6 H.sub.5                                                                        56      81      135   18 ± 1                                      CH.sub.2 --C.sub.6 H.sub.5                                                             81      140     210   27 ± 3                                      DDP      13      15.5    18    80 ± 8                                      Control                        25 ± 2                                      ______________________________________                                    

The platinum complexes of the invention may be compounded with suitablepharmaceutically acceptable carriers and administered orally,intramuscularly, topically, etc. It is preferred, however, to combinethe complex with suitable media, e.g., 5% dextrose, klucel, water, etc.,for intravenous administration. Care should be taken, however, to avoidthe use of saline as an i.v. medium.

Those skilled in the art will be aware of suitable carriers for thecomplexes of the invention suitable for formulation into capsules,tablets, powders, ointments, pellets, inc.

The complexes may also be administered in combination with otheranti-tumor agents in a combined chemotherapeutic regimen.

The amount of complex included in the pharmaceutical composition and thedosages of complex utilized in the method of treatment of the inventionwill vary depending in each case upon the condition of the patient, thenature of the tumor undergoing treatment, the anti-tumor activity of thecomplex, the toxicity and solubility characteristics thereof, etc.Generally, however, an amount of platinum complex ranging from about 25to about 200 mg/kg is adequate for most applications.

We claim:
 1. A water-soluble square-planar DACH cis-platinum(II)four-coordinate complex having the formula: ##STR6## wherein: X is amonovalent anion selected from the group consisting of, monosaccharate,saccharate-4-lactone, shikimate, isethionate, 2-aminoethylsulfate,azetidinecarboxylate, proline, hydroxyproline, pipecolinate,cyclopropanecarboxylate, cyclobutanecarboxylate,cyclopentanecarboxylate, cyclopentenecarboxylate,cyclohexanecarboxylate, cyclohexenecarboxylate, bicine, glycine,2-aminoethanesulfonate, 2-chloroethanesulfonate andY is a divalent anionselected from the group consisting of iminodiacetate, isocitratelactone,furanedicarboxylate, cyclopropane-1,1-dicarboxylate,isocitratomonoethylester, N-methyliminodiacetate,N-(2-hydroxyethyl)-iminodiacetate, N-benzyliminodiacetate,N-phenyliminodiacetate, N-(2-acetamido)iminodiacetate,cyclohexane-1,1-diacetate, trans-1,2-cyclopropanedicarboxylate,trans-1,2-cyclobutanedicarboxylate, trans-1,2-cyclopentanedicarboxylateand trans-1,2-cyclohexanedicarboxylate.
 2. A platinum complex of claim 1having the formula: ##STR7##
 3. A platinum complex of claim 1 having theformula: ##STR8##
 4. A platinum complex of claim 1 having the formula:##STR9##
 5. A platinum complex of claim 1 having the formula: ##STR10##6. A platinum complex of claim 1 having the formula: ##STR11##
 7. Aplatinum complex of claim 1 having the formula: ##STR12##
 8. A platinumcomplex of claim 1 having the formula: ##STR13##
 9. A platinum complexof claim 1 having the formula: ##STR14##
 10. A platinum complex of claim1 having the formula: ##STR15##
 11. A platinum complex of claim 1 havingthe formula: ##STR16##
 12. A platinum complex of claim 1 having theformula: ##STR17##
 13. A platinum complex of claim 1 having the formula:##STR18##
 14. A platinum complex of claim 1 having the formula:##STR19##
 15. A platinum complex of claim 1 having the formula:##STR20##
 16. A platinum complex of claim 1 having the formula:##STR21##
 17. A platinum complex of claim 1 having the formula:##STR22##
 18. A platinum complex of claim 1 having the formula:##STR23##
 19. A platinum complex of claim 1 having the formula:##STR24##
 20. A platinum complex of claim 1 having the formula:##STR25##
 21. A platinum complex of claim 1 having the formula:##STR26##
 22. A platinum complex of claim 1 having the formula:##STR27##
 23. A platinum complex of claim 1 having the formula:##STR28##
 24. A platinum complex of claim 1 having the formula:##STR29##
 25. A platinum complex of claim 1 having the formula:##STR30##
 26. A platinum complex of claim 1 having the formula:##STR31##
 27. A platinum complex of claim 1 having the formula:##STR32##
 28. A platinum complex of claim 1 having the formula:##STR33##
 29. A platinum complex of claim 1 having the formula:##STR34##
 30. A water-soluble square-planar DACH cis-platinum (II)four-coordinate complex having the formula: ##STR35## wherein Y isiminodiacetate, N-methyliminodiacetate,N-(2-hydroxyethyl)-iminodiacetate, N-phenyliminodiacetate orN-benzyliminodiacetate.
 31. A complex according to claim 38 which istrans-R,R-DACH-Pt(II).
 32. A platinum complex according to claim 1wherein the complex is iminodiacetato(DACH)Pt(II).
 33. A platinumcomplex according to claim 1 wherein the complex isiminodiacetato(trans-R,R-DACH)Pt(II).
 34. A platinum complex accordingto claim 1 wherein the complex is N-methyliminodiacetato(DACH)Pt(II).35. A platinum complex according to claim 1 wherein the complex isN-methyliminodiacetato(trans-R,R-DACH)Pt(II).
 36. A platinum complexaccording to claim 1 wherein the complex isN-(2-hydroxyethyl)iminodiacetato(DACH)Pt(II).
 37. A platinum complexaccording to claim 1 wherein the complex isN-(2-hydroxyethyl)iminodiacetato(trans-R,R-DACH)Pt(II).
 38. A platinumcomplex according to claim 1 wherein the complex isN-phenyliminodiacetato(DACH)Pt(II).
 39. A platinum complex according toclaim 1 wherein the complex isN-phenyliminodiacetato(trans-R,R-DACH)Pt(II).
 40. A platinum complexaccording to claim 1 wherein the complex isN-benzyliminodiacetato(DACH)Pt(II).
 41. A platinum complex according toclaim 1 wherein the complex isN-benzyliminodiacetato(trans-R,R-(DACH)Pt(II).
 42. A platinum complexaccording to claim 1 wherein the complex isN-(2-acetamido)-iminodiacetato(DACH)Pt(II).
 43. A platinum complexaccording to claim 1 wherein the complex isN-(2-acetamido)-iminodiacetato(trans,R,R-DACH)Pt(II).
 44. A platinumcomplex of claim 1 having the formula: ##STR36## wherein R is hydrogen,phenyl, 2-acetamido, methyl, 2-hydroxyethyl or benzyl.
 45. Apharmaceutical composition in unit dosage form suitable foradministration to an animal afflicted with tumor cells sensitive to aplatinum complex of claim 1 comprising a therapeutically anti-tumoreffective amount of said platinum complex and a pharmaceuticallyacceptable carrier therefor.
 46. The composition of claim 45 whereinsaid platinum complex has the formula: ##STR37##
 47. The composition ofclaim 45 wherein said platinum complex has the formula: ##STR38## 48.The composition of claim 45 wherein said platinum complex has theformula: ##STR39##
 49. The composition of claim 45 wherein said platinumcomplex has the formula: ##STR40##
 50. The composition of claim 45wherein said platinum complex has the formula: ##STR41##
 51. Thecomposition of claim 45 wherein said platinum complex has the formula:##STR42##
 52. The composition of claim 45 wherein said platinum complexhas the formula: ##STR43##
 53. The composition of claim 45 wherein saidplatinum complex has the formula: ##STR44##
 54. The composition of claim45 wherein said platinum complex has the formula: ##STR45##
 55. Thecomposition of claim 45 wherein said platinum complex has the formula:##STR46##
 56. The composition of claim 45 wherein said platinum complexhas the formula: ##STR47##
 57. The composition of claim 45 wherein saidplatinum complex has the formula: ##STR48##
 58. The composition of claim45 wherein said platinum complex has the formula: ##STR49##
 59. Thecomposition of claim 45 wherein said platinum complex has the formula:##STR50##
 60. The composition of claim 45 wherein said platinum complexhas the formula: ##STR51##
 61. The composition of claim 45 wherein saidplatinum complex has the formula: ##STR52##
 62. The composition of claim45 wherein said platinum complex has the formula: ##STR53##
 63. Thecomposition of claim 45 wherein said platinum complex has the formula:##STR54##
 64. The composition of claim 45 wherein said platinum complexhas the formula: ##STR55##
 65. The composition of claim 45 wherein saidplatinum complex has the formula: ##STR56##
 66. The composition of claim45 wherein said platinum complex has the formula: ##STR57##
 67. Thecomposition of claim 45 wherein said platinum complex has the formula:##STR58##
 68. The composition of claim 45 wherein said platinum complexhas the formula: ##STR59##
 69. The composition of claim 45 wherein saidplatinum complex has the formula: ##STR60##
 70. The composition of claim45 wherein said platinum complex has the formula: ##STR61##
 71. Thecomposition of claim 45 wherein said platinum complex has the formula:##STR62##
 72. The composition of claim 45 wherein said platinum complexhas the formula: ##STR63##
 73. The composition of claim 45 wherein saidplatinum complex has the formula: ##STR64##
 74. The composition of claim45 wherein said platinum complex has the formula: ##STR65##
 75. Thecomposition of claim 45 wherein said platinum complex has the formula:##STR66##
 76. The composition of claim 45 wherein said platinum complexhas the formula: ##STR67##
 77. The composition of claim 45 wherein saidplatinum complex has the formula: ##STR68##
 78. The composition of claim45 wherein said platinum complex has the formula: ##STR69##
 79. Thecomposition of claim 45 wherein said platinum complex has the formula:##STR70##
 80. The composition of claim 45 wherein said platinum complexhas the formula: ##STR71## wherein Y is iminodiacetate,N-methyliminodiacetate, N-(2-hydroxyethyl)-iminodiacetate,N-phenyliminodiacetate or N-benzyliminodiacetate.
 81. The composition ofclaim 80 wherein said complex is trans-R,R-DACH-Pt(II).
 82. Thecomposition of claim 81 wherein said platinum complex ismono-iminodiacetato-(trans-R,R-DACH)Pt(II) and aqueous complexesthereof.
 83. The composition of claim 81 wherein said platinum complexis mono-N-methyliminodiacetato-(trans-R,R,-DACH)Pt(II) and aqueouscomplexes thereof.
 84. The composition of claim 81 wherein said platinumcomplex is mono-N-hydroxyethyliminodiacetato-(trans-R,R-DACH)Pt(II) andaqueous complexes thereof.
 85. The composition of claim 81 wherein saidplatinum complex is mono-N-phenyliminodiacetato-(trans-R,R-DACH)Pt(II)and aqueous complexes thereof.
 86. The composition of claim 81 whereinsaid platinum complex ismono-N-benzyliminodiacetato-(trans-R,R-DACH)Pt(II) and aqueous complexesthereof.